Chen Wenwen, Xu Luxia, Guo Zhigang, Zhou Muya
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.
Curr Res Transl Med. 2025 Apr-Jun;73(2):103491. doi: 10.1016/j.retram.2024.103491. Epub 2024 Dec 31.
Cancer remains one of the most pressing health challenges worldwide. Recently, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising approach for treating hematological cancers. However, the translation of CAR-T cell therapy to solid tumors faces formidable obstacles, notably the immunosuppressive tumor microenvironment. Within solid tumors, CAR-T cells encounter a hostile milieu that promotes exhaustion and diminishes their long-term effectiveness against cancer cells. Optimizing the manufacturing process is paramount to ensuring the efficacy of CAR-T cell therapy in solid tumors. A critical aspect of this optimization lies in refining the composition of cell culture media. By supplementing basic culture media with specific additives, researchers aim to improve the behavior and functionality of CAR-T cells, thereby enhancing their therapeutic potential. This review delves into the culture media additives that have been investigated or show promise in modulating CAR-T cell phenotypes and enhancing their anti-tumor efficacy. We explore various types of additives and their mechanisms of action to mitigate exhaustion and augment persistence within the challenging solid tumor microenvironment. By shedding light on the latest advancements in culture media optimization for CAR-T cell therapy, this review aims to provide insights into novel strategies for overcoming the hurdles posed by solid tumors. Ultimately, these insights hold the potential to enhance the effectiveness of CAR-T cell therapy and improve outcomes for cancer patients.
癌症仍然是全球最紧迫的健康挑战之一。最近,嵌合抗原受体(CAR)-T细胞疗法已成为治疗血液系统癌症的一种有前景的方法。然而,CAR-T细胞疗法向实体瘤的转化面临巨大障碍,尤其是免疫抑制性肿瘤微环境。在实体瘤内,CAR-T细胞会遇到一个恶劣的环境,这会促进其耗竭并降低它们对癌细胞的长期有效性。优化制造工艺对于确保CAR-T细胞疗法在实体瘤中的疗效至关重要。这种优化的一个关键方面在于完善细胞培养基的成分。通过在基础培养基中添加特定添加剂,研究人员旨在改善CAR-T细胞的行为和功能,从而增强其治疗潜力。这篇综述深入探讨了已被研究或有望调节CAR-T细胞表型并增强其抗肿瘤疗效的培养基添加剂。我们探索了各种类型的添加剂及其作用机制,以减轻耗竭并增强在具有挑战性的实体瘤微环境中的持久性。通过揭示CAR-T细胞疗法培养基优化的最新进展,这篇综述旨在提供有关克服实体瘤带来的障碍的新策略的见解。最终,这些见解有可能提高CAR-T细胞疗法的有效性并改善癌症患者的治疗结果。